

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

FIRST PATIENT IMPLANT IN THE GLOBAL CLINICAL STUDY OF THE MonarQ TTVR® SYSTEM

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company has successfully completed the first patient implant in the Global Clinical Study of the MonarQ TTVR® system (the “**System**”). The procedure was performed by Dr. Raj Makkar, Associate Director of Smidt Heart Institute and Chief of Interventional Cardiology, and his team at Cedars Sinai Hospital in Los Angeles, CA, U.S.

The MonarQ TTVR® system is an innovative option specifically designed for treating Tricuspid Regurgitation. The System has a unique biodynamic attachment system that utilizes and preserves the heart’s natural motion to secure the implant to the native leaflets, distribute systolic loads, and minimize paravalvular leaks over a wide range of annulus sizes.

Reference is made to the Company's announcement dated June 10, 2021, regarding its acquisition of the MonarQ Transcatheter Tricuspid Valve Replacement technology (the "Technology") from inQB8 Medical Technologies, LLC when the Technology was still in pre-clinical stages. The Company owns the global rights to this Technology and any products developed therefrom. The successful completion of the first patient implant marks the official launch of the Global Clinical Study, representing a significant milestone in the Company's Tricuspid Regurgitation pipeline development.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET MonarQ TTVR® SYSTEM SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, July 14, 2025

As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN, Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP, Mr. Huacheng WEI as independent non-executive Directors.